US 12,419,902 B2
Anti-viral and anti-tumoral compounds
Rotem Sorek, Rehovot (IL); Aude Bernheim, Rehovot (IL); and Adl Jenny Millman Dayan, Rehovot (IL)
Assigned to YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
Appl. No. 17/442,198
Filed by YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
PCT Filed Mar. 29, 2020, PCT No. PCT/IL2020/050377
§ 371(c)(1), (2) Date Sep. 23, 2021,
PCT Pub. No. WO2020/202142, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/967,600, filed on Jan. 30, 2020.
Claims priority of provisional application 62/827,089, filed on Mar. 31, 2019.
Prior Publication US 2022/0175807 A1, Jun. 9, 2022
Int. Cl. A61K 31/708 (2006.01); A61K 31/7068 (2006.01); A61K 31/7072 (2006.01); A61P 31/12 (2006.01); C07K 14/195 (2006.01)
CPC A61K 31/708 (2013.01) [A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61P 31/12 (2018.01); C07K 14/195 (2013.01)] 4 Claims
 
1. A method of treating a disease in a subject in need, said method comprising administering a nucleoside analog that is derived from a nucleotide analog produced by a prokaryotic homolog of viperin (pVip), wherein said nucleoside analog comprises the nucleotide analog produced by the pVip without the phosphate residues, wherein said pVip has the amino acid sequence of SEQ ID NOs: 409-789, or wherein said pVip is encoded by a pVip gene comprising the sequence of one of SEQ ID Nos: 3-408—with—SEQ ID NOs: 411, 417, 421, 425, 431, 432, 433, 438, 439 and 440; wherein said administration treats the disease.